Scientific Zambon Pharma June 29, 2026 Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Institutional Zambon Pharma April 28, 2026 Cultipharm and Zambon Announce Strategic Agreement for the Development of Advanced Nutraceutical Product Lines
Scientific Zambon Biotech December 22, 2025 Zambon Biotech announces first patient dosed in Phase 3b ADIP clinical study of IPX203 in Parkinson’s disease
Scientific Zambon Pharma June 24, 2025 Zambon Announces Approval and Launch in China of the Intravenous Formulation of Fluimucil® (N-acetylcysteine)
Institutional Zambon Pharma February 26, 2025 Massimo Grandi joins Zambon as Chief Core Therapies Officer
Institutional ZCube September 24, 2024 Zcube - Zambon Research Venture leads a C$2 million investment round in canadian startup Hyivy Health
Institutional ZCube September 23, 2024 Open Accelerator: Zcube announces 5 Startups Selected for the New Edition Focused on Women’s Health and Femtech
